Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180111

SCHEMBL7180111

SCHEMBL7180111

NC(=O)c1cnc(O)c([N+](=O)[O-])c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MET P08581 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ GAA P10253 3/20 0.42
▸ PKM P14618 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ TSHR P16473 2/20 0.42
▸ LMNA P02545 6/20 0.41
▸ MAPT P10636 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ ERN1 O75460 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CASP6 P55212 1/20 0.40
▸ ATM Q13315 1/20 0.39
▸ CTPS1 P17812 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2637045 0.84 CASP6 (0.53) METALDH1A1TSHRLMNAERN1
SCHEMBL31423765 0.83 PARP1 (0.50) PARP1SMN1; SMN2CYP3A4METALDH1A1
SCHEMBL4170811 0.83 PARP1 (0.50) PARP1SMN1; SMN2CYP3A4METALDH1A1
SCHEMBL19692404 0.82 MAPT (0.42) PARP1CYP3A4ALDH1A1L3MBTL1LMNA
SCHEMBL16095613 0.81 PARP1 (0.49) PARP1SMN1; SMN2CYP3A4METALDH1A1
SCHEMBL805262 0.81 PARP1 (0.49) PARP1SMN1; SMN2CYP3A4METALDH1A1
SCHEMBL14243379 0.79 CASP6 (0.40) TSHRLMNATDP1CASP6
SCHEMBL18038271 0.79 MAPK1 (0.57) ALDH1A1L3MBTL1LMNAMAPTMEN1
SCHEMBL16096096 0.78 PARP1 (0.45) PARP1SMN1; SMN2CYP3A4METALDH1A1
SCHEMBL14243548 0.77 TSHR (0.38) TSHRLMNAMAPTERN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083886-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2024-03-14 — — US disclosed
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-12-07 — — US disclosed
EP-4229049-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-08-23 — — EP disclosed
EP-4229050-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-08-23 — — EP disclosed
CN-116547278-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 — — CN disclosed
CN-116547279-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 — — CN disclosed
WO-2022078380-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 — — WO disclosed
WO-2022078407-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 — — WO disclosed
US-10640488-B2 Antibacterial compounds AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2020-05-05 — — US disclosed
US-20200095225-A9 NEW ANTIBACTERIAL COMPOUNDS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2020-03-26 — — US disclosed
US-20190256495-A1 NEW ANTIBACTERIAL COMPOUNDS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2019-08-22 — — US disclosed
WO-2017211760-A1 NEW ANTIBACTERIAL COMPOUNDS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2017-12-14 — — WO disclosed
WO-2017211759-A1 NEW ANTIBACTERIAL COMPOUNDS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2017-12-14 — — WO disclosed
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors GLAXO GROUP LIMITED (GB) 2008-11-27 — — US disclosed
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors GLAXO GROUP LIMITED (GB) 2008-11-27 — — US disclosed
WO-2007067875-A2 PYRIDINYL SULFONAMIDE MODULATORS OF CHEMOKINE RECEPTORS GLAXO GROUP LIMTED (GB) 2007-06-14 — — WO disclosed
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 — — US disclosed
CN-1374952-A Benzimidazolone derivatives and their use as phosphodiesterase inhibibors FUJISAWA PHARMACEUTICAL CO (JP) 2002-10-16 — — CN disclosed
EP-1196391-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-17 — — EP disclosed
WO-2001005770-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200095225-A9 NEW ANTIBACTERIAL COMPOUNDS MRPL21, CLPP, NRDC PARP1 3030/4885SMN1; SMN2 4572/4885CYP3A4 3159/4885
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR PARP1 3586/4885SMN1; SMN2 1274/4885CYP3A4 1214/4885
US-20190256495-A1 NEW ANTIBACTERIAL COMPOUNDS MRPL21, CLPP, NRDC PARP1 3030/4885SMN1; SMN2 4572/4885CYP3A4 3159/4885
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors CCR2, CCR1, CCRL2 PARP1 3608/4885SMN1; SMN2 2031/4885CYP3A4 1414/4885
US-20240083886-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR PARP1 3441/4885SMN1; SMN2 1623/4885CYP3A4 1040/4885
US-10640488-B2 Antibacterial compounds MRPL21, CLPP, NRDC PARP1 2967/4885SMN1; SMN2 4549/4885CYP3A4 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.